Rizatriptan Benzoate Tablet
Product Images NDC 65862-600

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 65862-600). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
Figure 1 shows the Kaplan-Meier plot of the probability over time of obtaining headache response (no or mild pain) following treatment with rizatriptan benzoate or placebo. The averages displayed are based on pooled data from 4 placebo-controlled, outpatient trials providing evidence of efficacy (Studies 1, 2, 3, and 4). Patients taking additional treatment or not achieving headache response prior to 2 hours were censored at 2 hours. The chart displays the estimated probability of response based on the hours post-dose and the percentage rates for achieving an initial headache response. The data is presented for Placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
This is a figure and table that show the estimated probability of patients taking a second dose of Rizatriptan Benzoate or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled studies 1, 2, 3, and 4. The plot is based on data obtained in 4 placebo-controlled outpatient clinical trials and includes both patients who had headache response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose.*
FDA Label Image

Package Label-principal Display Panel (5 mg Unit-of-Use Pack (12 Tablets))

Package Label-principal Display Panel (5 mg Unit-of-Use Pack (12 Tablets))
This appears to be a table showing the percentage of a certain substance (possibly the drug Rizatriptan Benzoate) at different time intervals (0, 2, and 15 hours) between a placebo and orally disintegrating tablets. The table also includes a 95% confidence interval for the data presented. The purpose of the study is not specified.*
FDA Label Image

Package Label-principal Display Panel (10 mg Unit-of-Use Pack (12 Tablets))

Package Label-principal Display Panel (10 mg Unit-of-Use Pack (12 Tablets))
Rizatriptan Benzoate Tablets, USP is a medication available in two strengths: 2 tablets or 4 or 3 tablets. It requires a prescription to be purchased and is produced by a pharmaceutical company with the identifier NG 65862.509-12. The text also includes some unreadable characters.*
FDA Label Image

Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.